Abstract:BACKGROUND:Head and neck squamous cell carcinoma (HNSCC) is a common malignancy that emanates from the lips, mouth, paranasal sinuses, oropharynx, larynx, nasopharynx, and from other pharyngeal cancers. The availability of high-throughput expression data has made it possible to use global gene expression data to analyze the relationship between metabolic-related gene expression and clinical outcomes in HNSCC patients.METHOD:In this study, we used RNA sequencing (RNA-seq) data from the cancer genome atlas (TCGA), with validation in the GEO dataset to profile the metabolic microenvironment and define potential biomarkers for metabolic therapy.RESULTS:We extracted data for 529 patients and 327 metabolic genes (198 upregulated and 129 downregulated genes) in the TCGA database. Carbonic anhydrase 9 (CA9) and CA6 had the largest logFCs in the upregulated and downregulated genes, respectively. Our Cox regression model data showed 51 prognostic-related genes with lysocardiolipin acyltransferase 1 (LCLAT1) and choline dehydrogenase (CHDH) being associated with the highest risk (HR = 1.144, 95% CI = 1.044 ~ 1.251) and the lowest risk (HR = 0.580, 95% CI = 0.400 ~ 0.839) in HNSCC, respectively. We next used the ROC curve to evaluate whether the differentially expressed metabolic-related genes could serve as early predictors of HNSCC. The findings showed an AUC of 0.745 and 0.618 in the TCGA and GEO analysis, respectively. Besides, the ability for the genes to predict clinicopathological HNSCC status was analyzed and the data showed that the AUC for age, gender, grade, stage, T, M, and N was 0.520, 0.495, 0.568, 0.606, 0.577, 0.476, and 0.673, respectively, in the TCGA dataset. On the other hand, the AUC for age, gender, stage, T, M, N, smoking, and HPV16-pos was 0.599, 0.531, 0.622, 0.606, 0.616, 0.550, 0.614, 0.519, and 0.397, respectively, in the GEO dataset.CONCLUSION:Taken together, our study unearths a novel metabolic gene signature for the prediction of HNSCC prognosis based on the TCGA dataset. Our signature might point out the metabolic microenvironment disorders and provides potential treatment targets and prognostic biomarkers.

Glucose Metabolism and Glucose Transporters in Head and Neck Squamous Cell Carcinoma

Roles of GLUT-1 and HK-II Expression in the Biological Behavior of Head and Neck Cancer

Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors.

Glucose Metabolism and Glucose Transporters in Breast Cancer

Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells

Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment

Advancements in the study of glucose metabolism in relation to tumor progression and treatment

The potential therapeutic targets of glutamine metabolism in head and neck squamous cell carcinoma

Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma

Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer

Targeting glucose metabolism for HPV-associated cervical cancer: A sweet poison

Single-cell analyses reveal the metabolic heterogeneity and plasticity of the tumor microenvironment during head and neck squamous cell carcinoma progression

Glucose transporters in cancer – from tumor cells to the tumor microenvironment

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Changes in Protein Glycosylation in Head and Neck Squamous Cell Carcinoma

Perspectives of lipid metabolism reprogramming in head and neck squamous cell carcinoma: An overview

The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Head and Neck Squamous Cell Carcinoma

Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis

A Metabolic Gene Signature to Predict Overall Survival in Head and Neck Squamous Cell Carcinoma.

Hypoxia-derived molecular subtype and gene signature characterize prognoses and therapeutic responses in head and neck squamous cell carcinoma

Glucose metabolism reprogramming in gynecologic malignant tumors